Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1965 1
1971 1
1972 1
1974 1
1978 1
1982 5
1983 7
1984 5
1985 4
1986 1
1987 4
1988 7
1989 3
1990 3
1991 3
1992 7
1993 3
1994 7
1995 5
1996 3
1997 5
1999 7
2000 7
2001 8
2002 16
2003 18
2004 8
2005 12
2006 15
2007 25
2008 22
2009 24
2010 31
2011 36
2012 30
2013 35
2014 34
2015 37
2016 55
2017 58
2018 47
2019 52
2020 72
2021 82
2022 60
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

743 results
Results by year
Filters applied: . Clear all
Page 1
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome.
Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, Sakamoto T, Tsujita K, Hagiwara N, Miyazaki S, Ako J, Arai H, Ishii H, Origuchi H, Shimizu W, Takemura H, Tahara Y, Morino Y, Iino K, Itoh T, Iwanaga Y, Uchida K, Endo H, Kongoji K, Sakamoto K, Shiomi H, Shimohama T, Suzuki A, Takahashi J, Takeuchi I, Tanaka A, Tamura T, Nakashima T, Noguchi T, Fukamachi D, Mizuno T, Yamaguchi J, Yodogawa K, Kosuge M, Kohsaka S, Yoshino H, Yasuda S, Shimokawa H, Hirayama A, Akasaka T, Haze K, Ogawa H, Tsutsui H, Yamazaki T; Japanese Circulation Society Joint Working Group. Kimura K, et al. Among authors: hagiwara n. Circ J. 2019 Apr 25;83(5):1085-1196. doi: 10.1253/circj.CJ-19-0133. Epub 2019 Mar 29. Circ J. 2019. PMID: 30930428 Free article. Review. No abstract available.
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Yasuda S, et al. Among authors: hagiwara n. N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2. N Engl J Med. 2019. PMID: 31475793 Clinical Trial.
Response.
Akizuki M, Serizawa N, Ueno A, Hagiwara N. Akizuki M, et al. Among authors: hagiwara n. Chest. 2017 Mar;151(3):726-727. doi: 10.1016/j.chest.2017.01.022. Chest. 2017. PMID: 28279280 No abstract available.
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Naito R, et al. Among authors: hagiwara n. JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561. JAMA Cardiol. 2022. PMID: 35704345 Clinical Trial.
Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation.
Fukaya H, Ako J, Yasuda S, Kaikita K, Akao M, Matoba T, Nakamra M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H. Fukaya H, et al. Among authors: hagiwara n. Heart. 2021 Nov;107(21):1731-1738. doi: 10.1136/heartjnl-2021-319321. Epub 2021 Jul 14. Heart. 2021. PMID: 34261738 Clinical Trial.
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial.
Matoba T, Yasuda S, Kaikita K, Akao M, Ako J, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Matoba T, et al. Among authors: hagiwara n. JACC Cardiovasc Interv. 2021 Nov 8;14(21):2330-2340. doi: 10.1016/j.jcin.2021.07.045. JACC Cardiovasc Interv. 2021. PMID: 34736731 Free article. Clinical Trial.
Different Determinants of the Recurrence of Atrial Fibrillation and Adverse Clinical Events in the Mid-Term Period After Atrial Fibrillation Ablation.
Watanabe R, Nagashima K, Wakamatsu Y, Otsuka N, Yokoyama K, Matsumoto N, Otsuka T, Suzuki S, Hirata A, Murakami M, Takami M, Kimura M, Fukaya H, Nakahara S, Kato T, Hayashi H, Iwasaki YK, Shimizu W, Nakajima I, Harada T, Koyama J, Okumura K, Tokuda M, Yamane T, Tanimoto K, Momiyama Y, Nonoguchi N, Soejima K, Ejima K, Hagiwara N, Harada M, Sonoda K, Inoue M, Kumagai K, Hayashi H, Yazaki Y, Satomi K, Watari Y, Okumura Y; AF Ablation Frontier Registry Investigators. Watanabe R, et al. Among authors: hagiwara n. Circ J. 2022 Jan 25;86(2):233-242. doi: 10.1253/circj.CJ-21-0326. Epub 2021 Jul 3. Circ J. 2022. PMID: 34219078 Free article.
Message from the Editor-in-Chief.
Hagiwara N. Hagiwara N. Heart Vessels. 2016 Jul;31(7):1021. doi: 10.1007/s00380-016-0843-9. Heart Vessels. 2016. PMID: 27220343 Free article. No abstract available.
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Akao M, Yasuda S, Kaikita K, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H. Akao M, et al. Among authors: hagiwara n. Am Heart J. 2021 Jun;236:59-68. doi: 10.1016/j.ahj.2021.02.021. Epub 2021 Feb 28. Am Heart J. 2021. PMID: 33657403 Clinical Trial.
743 results